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Detecting the cancer cells in the peripheral blood, i.e. circulating tumor cell (CTC), have been considered as the
“liquid biopsy” and become a particular area of focus. A deep insight into CTC provides a potential alternative
method for early diagnosis of solid tumor. Previous studies showed that CTC counts could be regarded as an
indicator in tumor diagnosis, predicting clinical outcomes and monitoring treatment responses. In this report, we
utilize our facile and efficient CTC detection device made of hydroxyapatite/chitosan (HA/CTS) for rare cancer cells
isolation and enumeration in clinical use. A biocompatible and surface roughness controllable nanofilm was
deposited onto a glass slide to achieve enhanced topographic interactions with nanoscale cellular surface
components, anti-EpCAM (epithelial cell adhesion molecule, EpCAM) were then coated onto the surface of
nanosubstrate for specific capture of CTCs. This device performed a considerable and stable capture yields. We
evaluated the relationship performance between serial CTC changes and the changes of tumor volume/serum
tumor marker in gastrointestinal cancer patients undergoing anti-cancer treatments. The present study results
showed that changes in the number of CTC were associated with tumor burden and progression. Enumeration of
CTCs in cancer patients may predict clinical response. Longitudinal monitoring of individual patients during the
therapeutic process showed a close correlation between CTC quantity and clinical response to anti-cancer
therapy. Effectively capture of this device is capable of CTCs isolation and quantification for monitoring of cancer
and predicting treatment response.
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Rare circulating tumor cells (CTCs) are some special cancer cells
which detach from the primary solid tumor and/or metastasis then
circulate in peripheral blood [1]. CTCs have been considered as the
probable cause of fatal metastatic disease [1–3]. A better understand-
ing of the biology of CTCs may provide a potential alternative access
to solid tumor and further the study of tumor metastasis and disease
progression (regarded as a “liquid biopsy” for epithelial cancers) [4].
However, the acquisition and analysis of CTCs are still one of the
technically challenges because these cells are extremely rare (a few to
hundreds cells per milliliter) and mixed with a large number of
hematologic cells (109 cells per milliliter) [5,6]. Over the past decade,
some technologies have been developed to detect CTCs, including flow
cytometry [7] and size-based separation [8,9]. The immunomagnetic
separation-based CellSearch™ Assay is the only FDA-approved CTC
diagnostic technology for metastatic breast, prostate and colorectalcancers. Consequently, metastatic breast cancer patients with 5 or
more CTCs counts (enumerated by CellSearch-Veridex) in 7.5 mL
blood before treatments may suffer poor progression-free survival and
overall survival [5]. However, due to its low capture yield and high cost
Table 1. Comparison of the Fabrication Specifications Between the Previous Reported Methods
and the New Version of the HA-CTSNF
TiO2
Nanoparticles
HA-CTSNF New Version
of HA-CTSNF
Photoresist spinner parameter - 6000 r/h, 60 s 10000 r/h, 60 s
Nanosubstrate roughness 100-140 nm 170-250 nm 120-170 nm
Nanosubstrate area 1 cm × 1 cm 1 cm × 1 cm 2 cm × 2 cm
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patients to guide therapeutic choices has not been established [10,11].
Previously, we have reported a high efficient CTCs detection assay
using a horizontally packed TiO2 nanofibers [12]. The capture of CTCs
by this method mainly depends on the enhanced local topographic
interactions [13,14] between nano-components on cancer cell mem-
brane (e.g., microvilli and filopodia) and the antibody (anti-EpCAM
[15]) coated nanofibers, which improves the CTCs capture efficiency.
Due to the complex process control and special equipment for preparing
these special nanostructures, this method have been limited for high
throughput fabrication. It's urgent to develop a new device that is worth
popularizing in clinical practice for its simple manufacture, low cost and
convenient use.
Herein, based on our previous publications, we utilize our recent
CTC detection device made of hydroxyapatite/chitosan (HA/CTS),
optimized fromour previousworks (TiO2nanoparticles [16] andHA-CTS
nanofilms [17]) for rare cancer cells isolation and enumeration in clinical
use. Results showed that capture yields of more than 80% can be achieved
through the use of our substrate (new version of HA-CTSNF). Given the
high sensitivity and specificity of the new version ofHA-CTSNF substrate,
we validated the ability of isolation and enumeration of CTCs in totally 32
localized and metastatic gastrointestinal cancer patients and tested its
potential utility in monitoring response to anti-cancer therapy.
Materials and Methods
Materials
Hydroxyapatite (HA) in powder form was purchased from
Sigma Aldrich (St Louis, MO), chitosan (CTS) was obtained from
Haisheng Co., Ltd (Qingdao, China), 4-Maleimidobutyric acid
N-hydrosuccinimide (≥98% GMBS), 3-mercaptopropyl trimethox-
ysilane (95% MTPMS), paraformaldehyde (PFA), streptavidin
(1 mg mL−1 SA), biotinylated anti-human EpCAM/TROP1 antibody
(Goat IgG) were supplied by R&D systems (Minneapolis, MN).
Anti-human CD45-FITC (Ms IgG1, clone H130) and anti-
cytokeratin-PE (CAM5.2, conjugated with phycoerythrin) were
purchased from BD Biosciences (San Jose, CA). Triton X-100 and
4′, 6-diamidino-2-phenylindole dihydrochloride (DAPI) were pur-
chased from Sigma-Aldrich (St Louis, MO). Phosphate-Buffered Saline
(PBS 1X, 0.0067M PO43−), RPMI-1640 growth medium, dulbecco's
modified eagle medium (DMEM), Tween-20, fetal bovine serum
(FBS) and 0.25% Trypsin-EDTA (Gibco, 1X) were supplied by
Invitrogen (Carlsbad, CA). Colorectal cancer cell line (HCT116),
gastric cancer cell line (MGC803), cervical cancer cell line (HeLa) and
chronic myelogenous leukaemia cell line (K562) were harvested from
Hubei Key Laboratory of Tumor Biological Behaviors.
Blood samples. Whole blood samples from healthy donors were
obtained fromDepartment of Clinical Laboratory, Zhongnan Hospital
of Wuhan University according to a protocol by the Institutional
Review Board (IRB) and cancer patients' blood samples were obtained
from Department of Oncology, Zhongnan Hospital of Wuhan
University under a separate IRB-approved protocol. All blood samples
were collected into Anticoagulant tubes (EDTAK2, 2 ml, violet cap)
and processed within 12 h.
Fabrication of HA-CTS nanofilm substrate. According to our
previously established method[17], HA-CTS nanofilm (HA-CTSNF)
was prepared as below. Firstly, the glass substrate was boiled in Piranha
solution (3:1 (v/v) H2SO4/H2O2) at 100 °C for 1 h, washed several
times with deionized water, then treated by oxygen plasma treatment(PDC-32G, Harrick Plasma, USA) for 2 min, and dried with nitrogen
gas. A chitosan aqueous solution of 2 wt% was prepared by dissolving
chitosan powder into distilled water containing 2% acetic acid and then
5wt%nano-hydroxyapatite (HA) powder was added slowly. Themixed
solution was blended by magnetic stirrer for 12 h and then uniformly
coated on the clean glass by using a photoresist spinner (10000 r/h, 60
seconds). In the baking process the coated solutionwas heated onbake table
for 1 h. Following the baking process the HA-CTS nanofilm substrate was
soaked in 10 wt% NaOH solution for 10 h. Finally, the substrate was
washed with DI water, dried and ready for chemical modification. The
morphology of the HA-CTS nanofilm substrate was observed by Field
Emission Scanning Electron Microscopy (SEM, 6700 F, JEOL, Japan).
Compared to our previous works (Table 1), the new version of
HA-CTSNF has a larger surface area, higher transmittance, and equally
high capture efficiency. It may increase the “loading capacity” and enable
the anti-EpCAM modified HA-CTSNF to directly monitor the captured
cancer cells.
Surface modification with antibody. Surface modification proce-
dure for the HA-CTSNF was reported earlier [18]. The HA-CTSNF
substrate wasmodified with 4% (v/v) 3-mercaptopropyl trimethoxysilane
(MPTMS) in ethanol at room temperature for 1 h [19]. Then, the
substrate was treated with the coupling agent N-y-maleimidobutyryloxy
succinimide ester (GMBS, 0.25 mM) for 1 h make for GBMS
attachment to the substrate. Next, the substrate was treated with
streptavidin (SA) at room temperature for 45 min, resulting in
immobilization onto GMBS, and washed with 1 x PBS to remove excess
SA before immersed in biontinylated anti-EpCAM solution (10 μgmL−1
in PBS) for 60 min (RT).
Cell capture and identification. 1 mL cell suspension (i.e.,
HCT116,MGC803, HeLa and K562, 105 cells mL−1) was introduced
onto the new version of HA-CTSNF substrate and incubated for 1 h
(37°C and 5% CO2). Then, the chip was rinsed with PBS for 5 times.
The captured cells on the chip were fixed with 4% paraformaldehyde
(PFA) in PBS for 10 min. Then, the chip was loaded with 0.2% Triton
X-100 in PBS and incubated for 10 min in order to improve the
permeability of the cell and to allow for intracellular staining, 40 ul
blocking solution (2% donkey serum in PBS/0.2% triton X-100) was
added onto the chip and incubated for 30 min at room temperature,
followed by staining with PE-labeled anti-CK and FITC-labeled
anti-CD45 overnight. 4′, 6-diamidino-2-phenylindole dihydrochloride
(DAPI, 0.33 μg mL−1 in DI water) was used for staining nuclear for 10
min. Finally, detecting and counting of targeted cells using the
fluorescence microscope (IX81, Olympus, Tokyo, Japan). Captured
CTCs on chip were photographed by using IPP software (Media
Cybernetics Inc., Silver Spring, MD).
Cell capture from cancer patient blood samples. The circulating
tumor cells from cancer patient were captured according to the
procedure described below. About 4.0 mL patient peripheral blood
sample was introduced onto our chip and captured for 1 h. After
rinsing, followed by staining of anti-CK, anti-CD45 and DAPI, the
722 Enumeration of CTCs in cancer patients Cheng et al. Translational Oncology Vol. 7, No. 6, 2014specifically captured cancer cells were identified and counted on the
substrates directly.
Results and Discussion
The cancer cells capture principle of the HA-CTSNF substrate
was illustrated in Figure 1. The improved HA-CTSNF substrate
(New version of HA-CTSNF) was prepared by HA/CTS composites
(Figure 2A, see details inMaterials and Methods). A layer of
nanostructured film was fabricated onto a slide glass (Figure 2B).
The roughness of the nanostructured substrates were controlled by
changing the HA:CTS ratio. First, in order to demonstrate the surface
roughness of nanostructured film impacts the capture yields, the
biotin-HA-CTSNF substrate were prepared before cell capture
(Figure 2C), and two EpCAM-positive cancer cell lines (HCT116,
MGC803) were chosen and spiked into the Dulbecco's Modified
Eagle's Medium (DMEM) at a concentration of 105 mL−1, then,
these spiked cells were captured by anti-EpCAM-grafted substrates
which has been prepared with different surface roughness (ranging
from 20 to 280 nm). For comparison, two EpCAM-negative cancer
cell lines (K562 and HeLa) were chosen for specific cell capture
comparison experiments. As shown in Figure 2D, when the roughness
of the substrates was around 150 nm, maximal cell capture yields were
achieved for HCT116 cell line (approximately 81%) and MGC803
cell line (approximately 64%) while minor changes were observed for
EpCAM-negative cells. These results revealed that the effect of
roughness on the cell capture yields can be attributed to the local
topographic interactions between nano-substrate and cancer cells.
To determine the optimum incubation time for efficient cell
capture, we performed experiment about incubation times by using
the optimal substrate modified with anti-EpCAM as studied above.
Two EpCAM-positive cancer cell lines (HCT116 and BGC803) and
two EpCAM-negative cancer cell lines (K562 and Hela) were
examined. The cell capture yields with different incubation time were
shown in Figure 2E. For the EpCAM-positive cell line, the recovery
yields of cell capture increased with increasing incubation time and
significant changes had been observed, and the maximal recovery
yields achieved saturation at an incubation of 60 min or longer.
There was several times difference between the maximal recoveryFigure 1. Schematic of cancer cells capture principle of the HA-C
cell-capture-agent and cancer cell preferred nano-scaled topographyyields and the minimal recovery yields in our test, leading us to
ascertain 60 min to be the minimum time for optimal capture.
Finally, we tested these four cell lines on the new version of
HA-CTSNF under the optimal cell capture conditions, showed a
high capture efficiency of 72% to 84% with EpCAM-positive cell
lines (Figure 2F). New version of HA-CTSNF exhibited capture
efficiency equal to that of our previous works when we compare the
capture performance of new version of HA-CTSNF with HA-CTSNF
and TiO2 nanoparticles (Figure 2G).
During the clinical utility of our platform for rare cancer cells
capture from cancer patient peripheral blood samples, we evaluated
the relationship performance between serial CTCs changes and the
changes of tumor volume/serum tumor marker (i.e. CEA, CA19-9) in
gastrointestinal cancer patients who have received anti-cancer
treatments. Patients were followed up after discharge by physical
examination, routine blood tests, serum tumor marker tests, and
computed tomograms (CT scans) according to standard clinical
practice. In the patient information table (Table 2), CTC numbers
were calculated before and 10–18 weeks after the treatment initiation.
Medians and ranges were calculated on patients' age and their serum
CA19-9 and CEA concentrations. The frequencies and percentages
were calculated for the patients' clinical status. About 4.0 mL
peripheral blood samples were introduced onto our substrate for cell
capture, at the same time, 5 healthy donors' epithelia blood samples
were tested as control. Specifically captured CTCs (CK+/CD45−/
DAPI+, 10 μm b cell sizes b 30 μm) were identified from WBCs
(CK−/CD45+/DAPI+, sizes b15 μm) using fluorescence microsco-
py [20,21] (Figure 3A). CTC enumeration results obtained from 5
healthy donors and 32 cancer patients before treatment (12 gastric
cancer patients and 20 colorectal cancer patients) were showed in
Figure 3B. Cell counts of cancer patients ranging from 3 to 162 per
4.0 mL that were significantly higher than cells counts of healthy
donors (0-5 CTCs/4 mL). The CTCs changes corresponded with
tumor size (Figure 3, C–D), while the changes in CTCs did not
always keep consistent in serum tumor marker (Figure 3, E–F), as a
common phenomenon reported in early study (serum tumor marker
flare after starting chemo). The results showed that enumeration of
CTCs in cancer patients may predict clinical response to anti-cancerTSNF substrate. Capture efficiency was improved by combining
of substrate.
Figure 2. (A) Schematic procedure for the fabrication of the nanostructured film. (B) Scanning electron microscopy (SEM) image of
HA-CTSNF substrate. (C) Grafting of biotinylated epithelial-cell adhesion-molecule antibody (anti-EpCAM) onto HA-CTSNF substrate.
The cell capture yields of the HA-CTSNF substrate with (D) different surface roughness of nanostructured film ranging from 20 to 280 nm
and (E) at different incubation time (with incubation time of 15, 30, 45, 60 and 90 min). (F) Capture efficiencies of four different cell lines
at the optimal cell capture conditions. (G) Comparison of capture efficiency of new version of HA-CTSNF with two different controls:
(i) HA-CTSNF, (ii) TiO2 nanoparticles. Error bars show standard deviations (n = 3).
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performed considerable capture efficiency and allowed for monitoring
CTCs to evaluate the clinical treatment response and guide
therapeutic choices.
Longitudinal monitoring of individual patients during the
therapeutic process also showed a close correlation between CTC
quantity and clinical response. We serially monitored CTCs in
patient 9 with gastric cancer receiving SOX regimens (S-1 plus
Oxaliplatin) and total gastrectomy. As result shown in Figure 4 thatTable 2. Clinicopathologic Characteristics and CTC Numbers of Patients
Cancer Species Age
Median (Range)
CTC/4 ml
Median (Range)
Healthy control (n = 5) 25 (22-29) 2.2 (0-5)
Gastric cancer (n = 12) 58.2 (39-75) 35.75 (3-96)
Colon cancer (n = 20) 59.1 (38-80) 47.55 (4-162)declines in CTC number paralleled effective therapeutic interven-
tions. With clinical benefit, CTC number of this patient rapidly
decreased while serum CA19-9 concentrations also declined
gradually, at the same time, the tumor size and lymph node sizes
reduced obviously; irregularly thickening of gastric body near by the
pancreas was disappeared and could be separated from mass tissue as
shown in computed tomography image (Figure 4A). Another
phenomenon could be observed that a temporally increment in
CTC number during and after total gastrectomy and followed by aSerum CA19-9
[U/ml]
Median (Range)
Serum CEA
[ng/ml]
Median (Range)
Clinical Status
- - -
121.8 (2.69-N1000) 4.55 (0.74-35.5) I: 0 (0%)
II: 2 (16.67%)
III: 6 (50%)
IV: 4 (33.33%)
30.3 (2-304.7) 8.24 (0.49-39.72) I: (10%)
II: 7 (35%)
III: 7 (35%)
IV: 4 (20%)
Figure 3. (A) CTCs isolated from a colorectal cancer patient. Three-color immunocytochemistry method based on FITC-labeled anti-CD45,
PE-labeled anti-CK, and DAPI nuclear staining was applied to identify and enumerate CTCs from non-specifically trapped WBCs. (B) CTC
enumeration results obtained from healthy donors and cancer patients. Numerical analysis of 4 patients showing the number of CTCs
(red), concentration of serum CA19-9, CEA and tumor size (black) measured as the unidimensional sum of all significant tumor sites on a
CT scan. Imaging studies were assessed by a single reference radiologist (Haibin Song), who graded responses according to Response
Evaluation Criteria in Solid Tumors (RECIST). Type of treatment and duration are noted for each case. Patients with diagnoses and specific
therapies shown are (C) patient 6, gastric, SOX: S-1 plus Oxaliplatin, (D) patient 22, colorectal, FOLFOX 6: Oxaliplatin, 5-FU and leucovorin,
(E) Patient 7: gastric, SOX, f) Patient 19, colorectal, FOLFOX 6.
724 Enumeration of CTCs in cancer patients Cheng et al. Translational Oncology Vol. 7, No. 6, 2014drop. This result may indicate that surgical operation increase the
chance of cancer cells shed from solid tumor into the circulation.
Above all our study showed that the capture efficiency of HA-CTSNFFigure 4. Serial Changes of CTCs in cancer patient. (A) Computed tom
ii) after chemo and iii) after dissection. (B) Serial CTCs and serum CA1
are noted: Sox: S-1 plus Oxaliplatin, OPS: total gastrectomy.substrate is reliable and capable of longitudinal monitoring of cancer
and this approach may have early diagnostic potential. A prospective
trial would be needed to explore its predictive value.ography (CT) images in three different stages, i) before treatment,
9-9 changes of patient 9 are plotted. Type of treatment and duration
Translational Oncology Vol. 7, No. 6, 2014 Enumeration of CTCs in cancer patients Cheng et al. 725In conclusion, CTCs isolation based on our platform allowed the
longitudinal enumeration of cancer cells from cancer patients with
high capture yield. Regarding the ability of monitoring CTCs from
patient who are receiving clinical therapy, we expect this method is of
application potential for treatment responses monitor, patient
prognosis indication and cancer-related biological studies.
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